Point72 led a $30m Series A in Hinge Bio.

Point72, an investment firm, led a $30m Series A in Hinge Bio, a privately-held biotechnology company, with participation from Ridgeback Capital, InVivium Capital, and Lightswitch Capital. “Hinge Bio is committed to developing life-changing medicines for patients with intractable diseases. These funds will enable early clinical demonstration of the safety and efficacy of HB2198 in Lupus patients as well as the pre-clinical evaluation of a variety of other constructs of interest to both patients as well as pharmaceutical company partners,” Barry Selick, Hinge Bio Chief Executive Officer.